OnCusp Therapeutics

formerly OnCusp

Princeton, United States · Founded 2021 · $125.0M raised

Employees
11–50
Founded
2021
Business Model
B2B
Total Funding
$125.0M
Last Round
$100.0M Series AJan 2024
Rounds
2

About

OnCusp Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class oncology therapies, including antibody-drug conjugates (ADCs) and other targeted cancer treatments. Co-founded in 2021 by veterans from Merck, Novartis, and Daiichi Sankyo, the company advanced its lead asset CUSP06 — a CDH6-targeted ADC — into Phase 1 clinical trials and has raised $139M from investors including Novo Holdings and OrbiMed.

Summary

OnCusp Therapeutics is a Biotech company based in Princeton, United States, founded in 2021. It has raised $125.0M in total across 2 rounds, most recently a $100.0M Series A round in Jan 2024. Investors include OrbiMed, F-Prime Capital and Novo Holdings A/S.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Series ASeries AJan 2024
$100.0M

Sign up to see all 2 rounds

Seed through Series A — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

OnCusp Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/oncusp-therapeutics"><img src="https://indexed.vc/api/badge/company/oncusp-therapeutics" alt="OnCusp Therapeutics on Indexed.vc" width="260" height="76" /></a>